Welcome to our dedicated page for Repare Therapeutics news (Ticker: RPTX), a resource for investors and traders seeking the latest updates and insights on Repare Therapeutics stock.
Repare Therapeutics Inc. (Nasdaq: RPTX) is a clinical-stage precision oncology company whose news flow centers on synthetic lethality-based cancer drug development, portfolio monetization, and a planned acquisition by XenoTherapeutics, Inc. Company press releases describe a pipeline that includes RP-3467, a Phase 1 Polθ ATPase inhibitor, and RP-1664, a Phase 1 PLK4 inhibitor, as well as prior development of the PKMYT1 inhibitor lunresertib. News items frequently cover updates on the POLAR and LIONS clinical trials, scientific presentations, and strategic transactions.
Investors and researchers following RPTX news can expect detailed announcements on clinical trial milestones, such as enrollment updates and initial safety, tolerability and early efficacy data from Phase 1 studies. Repare’s disclosures also highlight licensing and collaboration agreements, including an exclusive worldwide license of lunresertib to Debiopharm and an out-licensing of discovery platforms and intellectual property to DCx Biotherapeutics. Additional coverage includes the asset purchase agreement with Gilead Sciences for the Polθ ATPase inhibitor RP-3467 and amendments to collaboration arrangements with partners such as Bristol-Myers Squibb.
A significant portion of recent news focuses on Repare’s strategic review and corporate transactions. The company has announced a definitive arrangement agreement under which XenoTherapeutics, Inc. and Xeno Acquisition Corp. will acquire all of Repare’s common shares through a court-approved plan of arrangement. Related releases describe expected cash consideration per share, the issuance of non-transferable contingent value rights, support and voting agreements with major shareholders, and anticipated delisting from the Nasdaq Global Select Market following closing.
This news page aggregates these company-issued updates, including business highlights, quarterly financial results, conference abstracts and presentations, and regulatory disclosures referenced in Form 8-K filings. Readers interested in RPTX can use this stream to monitor developments in Repare’s precision oncology programs, its partnerships, and the progress of the proposed acquisition and associated contingent value right structure.
Repare Therapeutics (RPTX) announced the acceptance of six abstracts for presentation at the AACR Annual Meeting 2025 in Chicago. The presentations include two mini-oral sessions and four poster presentations focusing on various oncology research developments.
The mini-oral presentations will feature the Phase I MYTHIC study results on the combination of PKMYT1-inhibitor lunresertib and ATR-inhibitor camonsertib in ovarian and endometrial cancers, and research on PLK4 inhibitor RP-1664 in neuroblastoma models.
The poster presentations will cover topics including:
- Dual mechanism of PLK4 inhibition sensitivity
- RP-1664's effects in TRIM37-high xenograft models
- Pan-cancer analysis of TRIM37 copy-number
- CCNE1 amplification targeting in gastric cancer
Repare Therapeutics (NASDAQ: RPTX) announced key leadership changes effective April 11, 2025. Steve Forte, current Executive Vice President and CFO, has been appointed as President, CEO, and Board Director, while maintaining his CFO role. Lloyd M. Segal has resigned from his positions as President, CEO, and Board Director to pursue other opportunities.
Forte, who joined Repare in 2019, brings over 20 years of finance and biotech leadership experience. He previously served as CFO at Clementia Pharmaceuticals, which was acquired by Ipsen for $1.3 billion. Additionally, Sandra Alves has been promoted from VP and Corporate Controller to Chief Accounting Officer.
The clinical-stage precision oncology company is currently advancing three Phase 1 trials: the MYTHIC trial (lunresertib with Debio 0123) expecting completion in Q2 2025, the POLAR trial (RP-3467) with data expected in Q3 2025, and the LIONS trial (RP-1664 with olaparib) with initial data expected in Q4 2025. The company is also exploring strategic alternatives and partnerships for lunresertib and camonsertib.
Repare Therapeutics (Nasdaq: RPTX) has announced the granting of stock options to two new employees through its 2024 Inducement Plan. The Compensation Committee approved two separate grants:
1. A stock option granted on November 5, 2024, with an exercise price of $3.59 per share
2. A stock option granted on March 5, 2025, with an exercise price of $1.17 per share
The total aggregate amounts to 22,200 common shares. Both options have ten-year terms and will vest over four years, with 25% vesting after one year and the remainder vesting in monthly installments. These grants were made as employment inducements in compliance with Nasdaq Listing Rule 5635(c)(4).
Repare Therapeutics (RPTX) has announced significant business restructuring and clinical updates for Q4 and full year 2024. The company is implementing a 75% workforce reduction while maintaining $152.8 million in cash reserves, extending runway to late-2027. Three key clinical trials are progressing with expected readouts in 2025:
- POLAR trial (RP-3467 Polθ inhibitor) data expected Q3 2025
- LIONS trial (RP-1664 PLK4 inhibitor) readout expected Q4 2025
- MYTHIC trial evaluating lunresertib combination therapy
Financial highlights include revenue from collaborations of $53.5 million for 2024, reduced R&D expenses of $115.9 million (down from $133.6 million in 2023), and a net loss of $84.7 million ($2.00 per share) for 2024.
Repare Therapeutics (RPTX) announced a strategic portfolio re-prioritization focusing on two Phase 1 clinical programs: RP-1664 (PLK4 inhibitor) and RP-3467 (Polθ ATPase inhibitor). The company will seek partnerships for its Lunre+Camo program before pivotal development.
The restructuring includes cost and headcount reductions, extending cash runway to mid-2027. With approximately $153 million in cash at 2024-end, Repare will concentrate on achieving near-term milestones, with initial clinical readouts expected in Q3 2025.
Key upcoming milestones include: RP-1664's Phase 1/2 expansion trial initiation in pediatric neuroblastoma (Q3 2025) and LIONS trial data (Q4 2025); RP-3467's POLAR trial data in Q3 2025. The company will discontinue development of lunresertib and camonsertib in other studies unless securing partnership agreements.
Repare Therapeutics (RPTX) reported positive results from its MYTHIC Phase 1 gynecologic expansion trial combining lunresertib and camonsertib (Lunre+Camo). The trial showed a 25.9% overall response rate in endometrial cancer and 37.5% in platinum-resistant ovarian cancer. Nearly half of patients maintained progression-free survival at 24 weeks.
The study included heavily pretreated patients, with many receiving the treatment as fourth line or beyond. In endometrial cancer patients, 100% had prior platinum therapy and 77.8% received immune checkpoint inhibitors. For ovarian cancer patients, all were platinum-resistant or ineligible, with 45.8% having received prior PARP inhibitors.
The company plans to initiate a registrational Phase 3 trial for endometrial cancer in second half of 2025.
Repare Therapeutics (Nasdaq: RPTX) announced a webcast presentation of data from its Phase 1 MYTHIC clinical trial on December 12, 2024. The trial evaluates the combination of lunresertib and camonsertib at the recommended Phase 2 dose in patients with platinum-resistant ovarian and endometrial cancers with specific genetic markers (CCNE1 amplification or FBXW7 or PPP2R1A mutations).
The presentation will feature Dr. Brian Slomovitz, Director of Gynecologic Oncology at Mount Sinai Medical Center, alongside Repare's executive management team. The event will be accessible via conference call and live video webcast through the company's investor relations website.
Repare Therapeutics has announced a Cooperative Research and Development Agreement (CRADA) with the US National Cancer Institute's Cancer Therapy Evaluation Program (CTEP) to advance camonsertib, their oral ATR inhibitor for cancer treatment. The drug has shown significant anti-tumor activity in preclinical and clinical studies, particularly demonstrating prolonged progression-free survival in ATM-mutated non-small cell lung cancer patients. Recent Phase 1 results combining camonsertib with radiotherapy showed complete responses in patients with ATM-altered tumors. CTEP will focus on combination studies involving camonsertib with radiation therapy and translational studies for biomarker identification.
Repare Therapeutics (RPTX) reported Q3 2024 financial results and clinical updates. The company ended Q3 with $179.4 million in cash and equivalents, expected to fund operations into H2 2026. Q3 net loss widened to $34.4 million ($0.81/share) from $18.9 million in Q3 2023. The company reduced workforce by 25% in August 2024 to focus on clinical-stage programs.
Key pipeline updates include upcoming MYTHIC trial data in December 2024, positive safety data presentation at EORTC-NCI-AACR, and first patient dosed in POLAR trial. The company plans to begin a registrational trial in 2025 for its lunresertib-camonsertib combination therapy in gynecologic cancers.
Repare Therapeutics (RPTX) presented updated data from its Phase 1 MYTHIC clinical trial, demonstrating successful management of anemia through an individualized dosing schedule of lunresertib (PKMYT1 inhibitor) and camonsertib (ATR inhibitor) combination therapy. The new schedule significantly reduced Grade 3 anemia rates to 22.6% from 51.4%, while maintaining clinical benefits. Key improvements include reduced red blood cell transfusions (13% vs 43%), fewer dose interruptions (13% vs 23%), and lower dose reductions (6% vs 17%). The trial showed no thrombocytopenia and no serious neutropenia, with maintained antitumor activity and radiographic regressions.
FAQ
What is the current stock price of Repare Therapeutics (RPTX)?
What is the market cap of Repare Therapeutics (RPTX)?
